home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

What 5 Analyst Ratings Have To Say About Sage Therapeutics ↗

March 09, 2023

Via Benzinga

Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone

March 08, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

February 28, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

February 22, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Expert Ratings for Sage Therapeutics ↗

December 06, 2022

Via Benzinga

Sage Therapeutics's Return On Capital Employed Insights ↗

December 05, 2022

Via Benzinga

Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗

October 17, 2022

Via Benzinga

Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

February 16, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' ↗

February 06, 2023

Via Benzinga

Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 06, 2023

From Biogen Inc.

Via GlobeNewswire

Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

February 02, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference

January 08, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 03, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

December 06, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

November 23, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

November 22, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

November 14, 2022

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

Via FinancialNewsMedia

Topics Retirement

Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

November 09, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

November 08, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer

November 01, 2022

From Sage Therapeutics

Via Business Wire

Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 25, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

October 17, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Mental Health Claims up 75% Since 2019

September 23, 2022

Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian...

Via PressReach

Mental Health Claims up 75% Since 2019

September 23, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75%...

Via FinancialNewsMedia

Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone

September 19, 2022

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗

September 09, 2022

On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 02, 2022

From Sage Therapeutics, Inc.

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com